Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aktis Oncology, Inc.AKTS · Entity 4711 | Director | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aktis Oncology, Inc.
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.09 · Expires 2036-04-15 | Direct | 37,866 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 37,866 · Balance 37,866 F1: 1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 15, 2026 Filed Apr 16, 2026 20:15 UTC | Aktis Oncology, Inc. AKTS · Entity 4711 | GrantStock Option (Right to Buy) · Derivative | 37,866 | $0.00 Strike: $18.09 | $0.00 |
DisclosureSEC source: 0001193125-26-159028 · ownership.xml · derivative · entry 1 Gormley Glenn · CIK 0002127198 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,866 Underlying: Common Stock · 37,866 shares Expires 2036-04-15 F1 · derivative.exercise_date: 1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.